Fund Evaluation Group’s Johnson & Johnson JNJ Stock Holding History

Fund Evaluation Group’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,862	Closed	-$1.36M	–	54
2018 Q3	$1.36M	Buy	9,862 +302	+3%	+$40.1K	0.23%	51
2018 Q2	$1.16M	Hold	9,560	–	–	0.18%	64
2018 Q1	$1.23M	Hold	9,560	–	–	0.14%	61
2017 Q4	$1.34M	Buy	+9,560	New	+$1.33M	0.14%	62

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fund Evaluation Group's JNJ Position: Q4 2018 in Review

Fund Evaluation Group sold out of Johnson & Johnson (JNJ) in Q4 2018, closing a stake of 9,862 shares — an estimated $1.36M sold.

Fund Evaluation Group first reported a position in JNJ in Q4 2017 and held it in 4 quarters. The position peaked at $1.36M in Q3 2018. 2,764 funds tracked by Wall St. Rank hold JNJ as of Q4 2018.

Fund Evaluation Group reported no remaining Johnson & Johnson position as of Q4 2018 after selling out during the quarter.
Fund Evaluation Group sold 9,862 Johnson & Johnson shares in Q4 2018, an estimated $1.36M.
Fund Evaluation Group first reported a position in Johnson & Johnson in Q4 2017 and held it in 4 quarters.
Fund Evaluation Group's Johnson & Johnson position peaked at $1.36M in Q3 2018.
2,764 funds tracked by Wall St. Rank held Johnson & Johnson as of Q4 2018.

Based on Fund Evaluation Group's 13F filing for Q4 2018, filed 12 Feb 2019.